OPK

OPKO Health, Inc. (OPK) | Rumor.io

OPKO Health

OPK

Attention (50-day avg)0%

Attention rank (50-day avg)#2,130

Bullish sentiment (50-day avg)21%

Price to earnings ratio-5.42

Market capitalization1.2B

Earnings per share-0.07

Dividend yield (TTM)—

Revenue (annual)606.9M

Net income (annual)-225.7M

Social

What share of all stock conversation is about OPK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 29

OPKO Health's stock price is $1.64 with no change in the last trade.
There is debate among investors about whether the current price is a value entry or a value trap.
Some investors are discussing the potential for a catalyst to push the stock price to double its current value, but there is no consensus on when this might happen.

Generated by AI

Sentiment

Of the messages about OPK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	57.14% +38.57	32.15% -38.29
Bearish	—	—	42.86% -38.57	67.85% +38.29

Bullish· Jul 28

OPKO Health delivers a massive Q2 beat, with revenue up 4.3% YoY and EPS beating expectations by ~25%.
The company's pharma revenue surged 59.8% to $89M, and guidance was raised to $560M–$585M for FY26.
OPKO Health's stock has been a strong performer, with a 33% increase in stock price and a 52-week high, driven by the company's solid Q2 earnings and massive volume.

Bearish· Mar 28

The company's financial management has been poor, with the board making decisions that have ruined shareholder value for years.
The company's revenue is expected to drop significantly, from $180 to $155, and cost-cutting measures have not been mentioned.
The company's strategy of selling assets piecemeal is a losing strategy for shareholders, and management may make a move to further harm the company.

Generated by AI

Topics

Of the messages about OPK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	100%	20.6%
Announcements	—	—	0%	50%
Controversies	—	—	0%	17.17%
Earnings	—	—	0%	7.94%
Analysts	—	—	0%	4.29%
Macro	—	—	0%	0%

Earnings· Oct 28

OPKO Health, Inc. (OPK) reported Q3 earnings of $0.04, beating the estimate of ($0.01).
Revenue was $385.80M, exceeding the estimate of $302.27M.
The company's cash position and revenue from services also showed improvement.

Analysts· Jul 31

Piper Sandler analyst Edward Tenthoff raised Opko Health's price target to $10 from $6 and maintained an Overweight rating after the company reported a Q2 earnings beat.
Opko Health's price target was also raised by Barrington Research to $7 from $4, with a maintained Outperform rating.
Analysts are highly confident in Opko Health, with a 100% buy consensus among 3 analysts, indicating strong confidence in the stock.

Announcements· Jun 28

The FDA has approved Pfizer's NGENLA, a long-acting once-weekly treatment for pediatric growth hormone deficiency, in partnership with Opko Health (OPK).
The approval covers patients aged three and older with growth hormone deficiency, and Opko Health's stock price has risen by 18.5% in response.
Opko Health's Chief Innovation Officer recently purchased 460,000 shares of the company's stock at an average price of $1.83, indicating confidence in the company's prospects.

Controversies· Aug 23

OPKO Health, Inc. (OPK) is facing a lawsuit investigation by Purcell Julie & Lefkowitz LLP, alleging potential breach of fiduciary duty.
The company has responded to the investigation, stating that the law firm did not contact them directly and that the allegations are baseless.
The law firm's investigation is seen by some as an attempt to manipulate the stock price, with potential insider buying expected as a result of the company's response.

Technical Analysis· Jun 28

OPKO Health, Inc. ($OPK) may be reversing off the $1.90 level based on its 5-minute chart.
A double bottom pattern is forming in $OPK with a support level of $1.66, indicating strong upside potential.
$OPK is showing signs of a bullish pattern with a cup and handle formation, and its MACD is getting ready to turn green.

Generated by AI

Community

Of the messages about OPK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	66.67%	59.78%	61.08%
Newcomers	—	33.33%	40.22%	38.92%

Regulars· Sep 2

The company's stock price has increased over 50% since May 15, 2026, and some investors believe it will continue to rise, potentially reaching $2.00 or higher.
The effective tradable float of the stock is low due to high ownership by hedge funds and insiders, creating a liquidity vacuum that could drive the stock price up.
BlackRock's significant purchase of 37 million shares is seen as a vote of confidence, making this a buying opportunity, and some investors believe the stock could reach over $2.00 soon.

Newcomers· Sep 29

Newcomers are considering whether to invest in OPKO Health, weighing the pros and cons of buying in at this price.
Investors are discussing potential targets and stop losses for OPKO Health, with some considering it a value entry or value trap.
There is debate among newcomers about the short-term and long-term viability of OPKO Health, with some discussing the risks of dilution and others looking for bullish signals.

Generated by AI

News

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.

1d agoYahoo Finance UK

Opko Health stock hits 52-week high at 1.74 USD

7d agoInvesting.com

OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?

8d agoYahoo Finance

The Bull Case For OPKO Health (OPK) Could Change Following New Mazdutide Royalty-Backed Financing Strategy

Earlier this month, OPKO Health expanded its financing relationship with HealthCare Royalty by issuing US$125 million in senior secured notes backed by future mazdutide royalty payments from China, allowing it to raise capital without issuing new shares and with total repayments capped at 1.5 times the amount received. This royalty-backed financing structure highlights how OPKO Health is using its metabolic therapy partnerships to access non-dilutive funding while preserving potential...

14d agoYahoo Finance

OPKO Health (OPK) Cashes In A Future Royalty Stream Early

On August 13, OPKO Health (NASDAQ:OPK) expanded its financing relationship with HealthCare Royalty, a business of KKR, issuing an additional $125 million in senior secured notes secured by the royalty stream tied to mazdutide, the GLP-1 drug OPKO licensed to Eli Lilly and now collects royalties on in China. The notes mature in 2044, matching […]

16d agoYahoo Finance

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

OPKO Health (NASDAQ:OPK) outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development. Speaking

19d agoYahoo Finance

Also Discussed

Investors talking about OPK also mention

#	Name	Attention
1	Cocrystal Pharma, Inc.COCP	0%+0
2	Co-Diagnostics Inc.CODX	0%+0
3	Labcorp Holdings Inc.LH	0%0
4	Quest Diagnostics IncorporatedDGX	0%0
5	Aytu BioPharma, Inc.AYTU	0%0
6	iBio, Inc.IBIO	0%0
7	HTBX - Heat Biologics, Inc.	——
8	Inovio Pharmaceuticals Inc.INO	0%+0
9	Halozyme Therapeutics Inc.HALO	0%0
10	T2 Biosystems, Inc.TTOO	0%new

OPKO Health, Inc.

Healthcare
Diagnostics & Research

OPKO Health, Inc. is a diversified healthcare company focused on diagnostics and pharmaceuticals. Through its Diagnostics segment, the company provides clinical laboratory and genetic testing services, including BioReference Health and specialized assays used in disease detection, monitoring, and patient management. Its Pharmaceutical segment markets approved therapies and supports development programs across areas such as kidney disease, hormone-related disorders, oncology, and infectious diseases. OPKO Health also works with commercial partners and maintains manufacturing, supply, and research activities across several international markets. The company plays a broad role in the healthcare market by combining testing services, marketed medicines, and pipeline assets within a single operating platform. OPKO Health, Inc. is headquartered in Miami, Florida.

Website

Location

4400 Biscayne Boulevard

Miami, FL, 33137

United States

Social

What share of all stock conversation is about OPK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 29

OPKO Health's stock price is $1.64 with no change in the last trade.
There is debate among investors about whether the current price is a value entry or a value trap.
Some investors are discussing the potential for a catalyst to push the stock price to double its current value, but there is no consensus on when this might happen.

Generated by AI

Sentiment

Of the messages about OPK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	57.14% +38.57	32.15% -38.29
Bearish	—	—	42.86% -38.57	67.85% +38.29

Bullish· Jul 28

OPKO Health delivers a massive Q2 beat, with revenue up 4.3% YoY and EPS beating expectations by ~25%.
The company's pharma revenue surged 59.8% to $89M, and guidance was raised to $560M–$585M for FY26.
OPKO Health's stock has been a strong performer, with a 33% increase in stock price and a 52-week high, driven by the company's solid Q2 earnings and massive volume.

Bearish· Mar 28

The company's financial management has been poor, with the board making decisions that have ruined shareholder value for years.
The company's revenue is expected to drop significantly, from $180 to $155, and cost-cutting measures have not been mentioned.
The company's strategy of selling assets piecemeal is a losing strategy for shareholders, and management may make a move to further harm the company.

Generated by AI

Topics

Of the messages about OPK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	100%	20.6%
Announcements	—	—	0%	50%
Controversies	—	—	0%	17.17%
Earnings	—	—	0%	7.94%
Analysts	—	—	0%	4.29%
Macro	—	—	0%	0%

Earnings· Oct 28

OPKO Health, Inc. (OPK) reported Q3 earnings of $0.04, beating the estimate of ($0.01).
Revenue was $385.80M, exceeding the estimate of $302.27M.
The company's cash position and revenue from services also showed improvement.

Analysts· Jul 31

Piper Sandler analyst Edward Tenthoff raised Opko Health's price target to $10 from $6 and maintained an Overweight rating after the company reported a Q2 earnings beat.
Opko Health's price target was also raised by Barrington Research to $7 from $4, with a maintained Outperform rating.
Analysts are highly confident in Opko Health, with a 100% buy consensus among 3 analysts, indicating strong confidence in the stock.

Announcements· Jun 28

The FDA has approved Pfizer's NGENLA, a long-acting once-weekly treatment for pediatric growth hormone deficiency, in partnership with Opko Health (OPK).
The approval covers patients aged three and older with growth hormone deficiency, and Opko Health's stock price has risen by 18.5% in response.
Opko Health's Chief Innovation Officer recently purchased 460,000 shares of the company's stock at an average price of $1.83, indicating confidence in the company's prospects.

Controversies· Aug 23

OPKO Health, Inc. (OPK) is facing a lawsuit investigation by Purcell Julie & Lefkowitz LLP, alleging potential breach of fiduciary duty.
The company has responded to the investigation, stating that the law firm did not contact them directly and that the allegations are baseless.
The law firm's investigation is seen by some as an attempt to manipulate the stock price, with potential insider buying expected as a result of the company's response.

Technical Analysis· Jun 28

OPKO Health, Inc. ($OPK) may be reversing off the $1.90 level based on its 5-minute chart.
A double bottom pattern is forming in $OPK with a support level of $1.66, indicating strong upside potential.
$OPK is showing signs of a bullish pattern with a cup and handle formation, and its MACD is getting ready to turn green.

Generated by AI

Community

Of the messages about OPK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	66.67%	59.78%	61.08%
Newcomers	—	33.33%	40.22%	38.92%

Regulars· Sep 2

The company's stock price has increased over 50% since May 15, 2026, and some investors believe it will continue to rise, potentially reaching $2.00 or higher.
The effective tradable float of the stock is low due to high ownership by hedge funds and insiders, creating a liquidity vacuum that could drive the stock price up.
BlackRock's significant purchase of 37 million shares is seen as a vote of confidence, making this a buying opportunity, and some investors believe the stock could reach over $2.00 soon.

Newcomers· Sep 29

Newcomers are considering whether to invest in OPKO Health, weighing the pros and cons of buying in at this price.
Investors are discussing potential targets and stop losses for OPKO Health, with some considering it a value entry or value trap.
There is debate among newcomers about the short-term and long-term viability of OPKO Health, with some discussing the risks of dilution and others looking for bullish signals.

Generated by AI

OPKO Health

Social

Sep 29

Bullish· Jul 28

Bearish· Mar 28

Earnings· Oct 28

Analysts· Jul 31

Announcements· Jun 28

Controversies· Aug 23

Technical Analysis· Jun 28

Regulars· Sep 2

Newcomers· Sep 29

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

Opko Health stock hits 52-week high at 1.74 USD

OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?

The Bull Case For OPKO Health (OPK) Could Change Following New Mazdutide Royalty-Backed Financing Strategy

OPKO Health (OPK) Cashes In A Future Royalty Stream Early

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

Also Discussed

OPKO Health, Inc.

Company Information

Location

Social

Sep 29

Bullish· Jul 28

Bearish· Mar 28

Earnings· Oct 28

Analysts· Jul 31

Announcements· Jun 28

Controversies· Aug 23

Technical Analysis· Jun 28

Regulars· Sep 2

Newcomers· Sep 29

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

Opko Health stock hits 52-week high at 1.74 USD

OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?

The Bull Case For OPKO Health (OPK) Could Change Following New Mazdutide Royalty-Backed Financing Strategy

OPKO Health (OPK) Cashes In A Future Royalty Stream Early

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

Also Discussed